ArticleDiscover oncology2025
Single‑cell RNA sequencing reveals TMEM71 as an immunomodulatory biomarker predicting immune checkpoint blockade response in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Gut microbiota and its metabolites: Key factors of drug resistance in the treatment of advanced prostate cancer (Review).Molecular medicine reports · 2026Review
- PINK1‑mediated mitophagy enhances breast cancer proliferation through metabolic reprogramming.Oncology reports · 2026Article
- Metabolic reprogramming-a breakthrough point in overcoming resistance to BRAF mutant melanoma targeted therapy (Review).Oncology letters · 2026Review
- TMEM70 drives breast cancer progression via mitochondrial oxidative phosphorylation and microenvironment remodeling.Cancer cell international · 2026Article
- Identification of senescence-related genes as diagnostic biomarkers for gastric cancer using bioinformatics and machine learning.Discover oncology · 2026Article
- Mapping research trends in immune cell metabolic reprogramming in breast cancer: a parallel dual-database bibliometric study.Discover oncology · 2026Article
- Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study.Oncology letters · 2026Article
- The Carcinogenic Role of HMGB1 and NF-κB in Gastric Adenocarcinoma.Digestive diseases and sciences · 2026Article
- MiR-362-3p inhibits the proliferation, migration and EMT of gastric cancer cells by regulating the DEP-1/ERK signaling pathway.Scientific reports · 2026Article
- TMEM132A is associated with metabolic reprogramming, macrophage-oriented immune remodeling, and breast cancer progression.Clinical and experimental medicine · 2026Article
- Review
- Article
- Integrative multi-omics analysis reveals an 11-gene malignant-myeloid interaction signature and identifies TPST1 as a potential regulator of immunosuppressive microenvironment in glioma.Discover oncology · 2026Article
- MX1Journal of translational medicine · 2026Article
- HOXB2 is a prognostic biomarker and correlated with immune infiltration in colorectal cancer and glioma.Discover oncology · 2026Article
- Integrated analysis reveals GSTA1 as a prognostic biomarker in stage I lung adenocarcinoma.BMC cancer · 2026Article
- Comparison of the safety and efficacy of different neoadjuvant therapy cycles for locally advanced gastric cancer: a retrospective propensity score-matched cohort study.World journal of surgical oncology · 2026Article
- A novel ferroptosis- and endoplasmic reticulum stress-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer.Discover oncology · 2026Article
- DMBX1 expression in colon cancer and its impact on prognosis and the tumor microenvironment.BMC medical genomics · 2026Article
- Identification of TMEM59L as a potential diagnosis, prognosis and immunotherapy biomarker for colon adenocarcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTMEM71 is a poorly characterized transmembrane protein with unclear roles in cancer. This study aimed to explore its prognostic value, immune relevance, and therapeutic implications in breast cancer.
methodsWe integrated transcriptomic, single-cell RNA-seq, immune infiltration and drug response data from TCGA, GTEx, GEO and public scRNA-seq datasets. Prognostic analysis, immune correlation (ssGSEA, CIBERSORT), functional enrichment (GO, KEGG, GSEA) and chemotherapy/immunotherapy sensitivity assessments were conducted.
resultsTMEM71 was significantly downregulated in breast cancer and correlated with poor clinical outcomes. Single-cell analysis revealed its predominant expression in malignant and stromal cells. TMEM71 expression was associated with enhanced infiltration of immune cells, upregulation of immune checkpoints and enrichment of immune-related pathways. High TMEM71 expression predicted better response to immune checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4) and greater sensitivity to chemotherapeutics, including Gemcitabine, 5-fluorouracil and paclitaxel.
conclusionTMEM71 is a novel immune-related gene with potential as a prognostic biomarker and predictor of therapy response in breast cancer. These findings offer new insights into the immunological role of TMEM71 and support its potential utility in guiding personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.